Trial Profile
A Preliminary Study of Sublingual Fentanyl for the Management of Breakthrough Pain Analgesia in Patients With Advanced Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 May 2021
Price :
$35
*
At a glance
- Drugs Fentanyl (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- 28 Jul 2020 Status changed from active, no longer recruiting to discontinued.
- 29 Mar 2018 Planned End Date changed from 1 Feb 2019 to 1 Feb 2021.
- 29 Mar 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2020.